Main Answer:
Survanta is a synthetic surfactant used to treat respiratory distress syndrome in premature infants.
Step-by-step explanation:
Survanta, a synthetic surfactant, plays a crucial role in managing respiratory distress syndrome (RDS) among premature infants. RDS is a condition where the infant's lungs lack sufficient surfactant, a substance that helps the air sacs in the lungs stay open, making breathing easier. Premature infants often have underdeveloped lungs, leading to difficulties in breathing. The introduction of Survanta helps alleviate these challenges by providing the necessary surfactant.
This synthetic surfactant is administered directly into the infant's lungs, facilitating the expansion and stabilization of the air sacs. By doing so, Survanta promotes improved lung function, aiding in the infant's ability to breathe more effectively. This intervention is particularly vital in the early stages of life when the respiratory system is still developing. Survanta essentially acts as a replacement for the natural surfactant that premature infants lack, offering crucial support during a critical phase of their pulmonary development.
In conclusion, Survanta serves as a lifeline for premature infants facing respiratory distress syndrome, addressing a fundamental challenge in their lung function. Its administration marks a significant advancement in neonatal care, contributing to better outcomes for these vulnerable infants.